Oncological Pharmacology

Oncological Pharmacology — Expert Level Guide

How it begins

Análisis exhaustivo de los mecanismos de acción, clasificación, farmacocinética, toxicología, resistencia y correlaciones clínicas de los agentes antineoplásicos empleados en medicina moderna.

What it covers

1. Oncological Pharmacology
2. 1. Introduction to Oncological Pharmacology
3. · 1.1 Fundamental Therapeutic Principles
4. · 1.2 Molecular Basis of Cancer Relevant to Pharmacology
5. 2. Cell Cycle and Pharmacological Targets
6. · 2.1 Cellular Cycle Regulatory Machinery
7. · 2.2 Classification by Phase Specificity
8. 3. Pharmacokinetics in Oncology
9. · 3.1 Absorption
10. · 3.2 Distribution
11. · 3.3 Metabolism
12. · 3.4 Elimination
13. · 3.5 Population Pharmacokinetics and PK/PD Modeling
14. 4. Leasing Agents
15. · 4.1 Nitrogenated Mustards
16. · 4.2 Nitrosoureas
17. · 4.3 Platinums (Platinum Analogues)
18. · 4.4 Other Alkylating Agents
19. 5. Antimetabolites
20. · 5.1 Folate Antagonists
21. · 5.2 Pyrimidine Analogues
22. · 5.3 Purine Analogues
23. 6. Antitumor Antibiotics
24. · 6.1 Anthracyclines
25. · 6.2 Bleomycin
26. · 6.3 Mitomycin C
27. · 6.4 Actinomycin D (Dactinomycin)
28. 7. Vegetable Alkaloids and Derivatives
29. · 7.1 Vinca Alkaloids (Vinca rosea)
30. · 7.2 Taxanes (Yew Bark, Taxus brevifolia)
31. · 7.3 Topoisomerase Inhibitors
32. 8. Hormonal and Anti-Hormonal Agents
33. · 8.1 Selective Estrogen Receptor Modulators (SERMs)
34. · 8.2 Aromatase Inhibitors (AIs)
35. · 8.3 Fulvestrant
36. · 8.4 Androgen Deprivation (ADT) in Prostate Cancer
37. 9. Kinase Inhibitors (TKIs)
38. · 9.1 BCR-ABL inhibitors
39. · 9.2 EGFR inhibitors
40. · 9.3 ALK inhibitors
41. · 9.4 BRAF/MEK inhibitors
42. · 9.5 CDK4/6 inhibitors
43. · 9.6 VEGFR (Multitarget Tyrosine Kinase) Inhibitors
44. · 9.7 Other TKIs of Clinical Relevance
45. 10. Monoclonal Antibodies (mAbs)
46. · 10.1 Nomenclature and Types
47. · 10.2 Anti-HER2
48. · 10.3 Anti-VEGF
49. · 10.4 Anti-EGFR (CRC)
50. · 10.5 Antibodies Conjugated to Drugs (ADCs)
51. 11. Oncological immunotherapy
52. · 11.1 Immune Checkpoint Inhibitors (ICIs)
53. · 11.2 Adoptive Cellular Therapy
54. · 11.3 Bispecific Antibodies
55. 12. Other Molecular Targets
56. · 12.1 PI3K/AKT/mTOR inhibitors
57. · 12.2 PARP inhibitors
58. · 12.3 Proteasome Inhibitors
59. · 12.4 Immunomodulatory Drugs (IMiDs)
60. · 12.5 IDH inhibitors
61. · 12.6 Hedgehog Pathway Inhibitors
62. · 12.7 BTK Inhibitors
63. · 12.8 BCL-2 inhibitors
64. 13. Drug Resistance in Oncology
65. · 13.1 Mechanisms of Resistance to Cytotoxics
66. · 13.2 Mechanisms of Resistance to TKIs
67. · 13.3 Resistance to ICIs
68. · 13.4 Strategies to Overcome Resistance
69. 14. Toxicity and Management of Adverse Effects
70. · 14.1 Myelosuppression
71. · 14.2 Nausea and Vomiting induced by Chemotherapy (CINV)
72. · 14.3 Mucositis
73. · 14.4 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
74. · 14.5 Tumor Lysis Syndrome (TLS)
75. · 14.6 Vesicant Extravasation Syndrome
76. 15. Drug Interactions in Oncology
77. · 15.1 Critically Important Drug Interactions
78. · 15.2 Interactions with Anticoagulants
79. · 15.3 Pharmacodynamic Interactions
80. 16. Special Populations
81. · 16.1 Kidney Failure
82. · 16.2 Liver Failure
83. · 16.3 Geriatric Oncology
84. · 16.4 Pregnancy and Cancer
85. 17. Principles of Combination Therapy
86. · 17.1 Emblematic Combination Protocols
87. · 17.2 Concept of Dose Intensity
88. · 17.3 Pharmacological Synergy
89. 18. Emerging Therapies and Future Perspectives
90. · 18.1 PROTACs and Protein Degraders
91. · 18.2 Therapeutic Vaccines against Cancer
92. · 18.3 Radiopharmaceutical Therapies
93. · 18.4 Epigenetic Degraders and Modulators
94. · 18.5 Therapies Directed at DNA and Repair
95. · 18.6 Precision Oncology and Tumor Agnostic Approvals
96. · 18.7 Signaling Antagonists in the Tumor Microenvironment
97. · 18.8 Artificial Intelligence in Oncological Pharmacology